Suven Life Sciences, a biopharmaceutical company specialized in CRAMS for global life sciences companies and drug discovery and developmental activities in CNS disorders, has posted standalone net profit growth of 8.8 per cent during the fourth quarter ended March 2017 to Rs.40.31 crore from Rs.37.07 crore in the corresponding period of last year basically due to lower tax provision.
The company provided Rs.4.28 crore for tax as against Rs.8.77 crore in the same period of last year. Its EBDITA declined slightly to Rs.53.10 crore from Rs.53.19 crore. EPS worked out to Rs.3.17 as compared to Rs.2.91.
For the full year ended March 2017, Suven's consolidated net sales increased by 7.8 per cent to Rs.539.17 crore from Rs.500.28 crore in the previous year. Its CRAMS sales increased by 10.6 per cent to Rs.516.70 crore from Rs.467.11 crore and that of DDDSS declined by 14.3 per cent to Rs.27.78 crore from Rs.32.41 crore. Its net profit has taken strong jump of 22 per cent and reached at Rs.87.09 crore from Rs.71.40 crore. EBDITA also increased by 24.1 per cent to Rs.150.16 crore from Rs.120.976 crore. EPS increased to Rs.6.84 as against Rs.5.61 in the last year. Its R&D expenditure increased to Rs.99.15 crore from Rs.90.35 crore. The company paid interim dividend of 100 per cent and will be treated as final dividend for the year 2016-17.
Suven life's
